Method for reverse analysis of polyorthoester raw materials and its application
Through reverse analysis method and high-performance liquid chromatography, the problem of polyorthoester monomer formulation detection in the prior art is solved, accurate detection of polyorthoester and quality control of slow-release auxiliary materials is achieved, and slow-controlled control is improved Release the effect.
Patent Information
- Application Number
- CN202411161483.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-08-23
AI Technical Summary
The existing detection methods cannot accurately analyze the monomer formulation content in polyorthoester, especially in complex prescriptions, and conventional analysis methods cannot be used to detect polyorthoester auxiliary materials, resulting in difficulty in slow release effect. control.
The reverse analysis method was used to degrade polyortholic acid ester in vitro and analyze its monomer ratio by high performance liquid chromatography. Combined with gradient elution and gradient chromatography conditions, the content of glycolic acid, triethylene glycol and propionic acid was determined to calculate the Monomer ratio.
It realizes efficient and accurate detection of polyorthoesters, which is simple and fast, and can qualitatively and quantitatively analyze a variety of degraded impurities, improving the quality control of POE and the analytical ability of bupivacaine-meloxicam sustained-release solution prescription.
Smart Images

Figure CN118671248B_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medical detection, and in particular relates to a method for reversely analyzing polyorthoester raw materials and application thereof. Background Art
[0002] Poly(ortho esters) is a new type of biodegradable polymer sustained-release material. Since its first synthesis, it has attracted the attention of many scholars due to its unique properties. Poly(ortho esters) (POE) is a synthetic biodegradable polymer material, which is prepared by condensing polybasic ortho acids or polybasic ortho esters with polyols under anhydrous conditions to form orthoester bonds. Its degradation in the body is due to the penetration of water into the polymer, which hydrolyzes the ester bonds in POE, thereby causing surface degradation and bulk degradation. As a polymer material, POE can entrain a variety of target drugs to achieve a sustained-release effect. At the same time, the water-soluble small molecules after degradation can be metabolized by the organism. It is an ideal sustained-release material and can be used as the main excipient to complete the clinical application of a variety of sustained-release preparations.
[0003] At present, conventional nuclear magnetic resonance detection is usually used to detect the molar ratio of monomers in mixed copolymers. Due to the expensive instrument, difficult analysis, and large error in the test results, it is not conducive to the routine detection of POE monomer ratio, and it cannot cope with the analysis of polyorthoester excipients in complex prescriptions. For the application of POE, it is currently mainly used as an excipient for bupivacaine-meloxicam sustained-release solution, and the prescription has been clinically applied. The sustained-release effect is significant and the price is expensive. POE is a mixed copolymer, and it is relatively difficult to synthesize excipients with ideal sustained-release effect, and conventional analytical methods cannot be applied to detection. Therefore, there is an urgent need for a highly specific and accurate analytical method to detect the content of multiple degradation impurities (glycolic acid, triethylene glycol, propionic acid) of POE in vitro. Calculating the proportion of monomers by content is extremely important for analyzing the prescription of bupivacaine-meloxicam sustained-release solution and controlling POE. Currently, the GC-MS method can be used to detect individual poly(oxyethyl)ester degradation impurities, but there are several insurmountable shortcomings. The first is that glycolic acid decomposes when heated to boiling point and cannot be analyzed by GC; the second is that the degradation process is carried out in an aqueous environment, and GC analysis requires an evaporation and re-dissolution process, and reproducibility and recovery rate cannot be guaranteed; the third is that the formulation of the preparation is complex, and the specificity of GC-MS analysis is poor. Summary of the invention
[0004] The technical problem to be solved by the present invention is to overcome the above-mentioned defects of the prior art and provide a method for reverse analysis of poly(orthoester) raw materials. By degrading POE in vitro and performing high performance liquid chromatography to analyze the formula content of monomers in the raw materials of the original POE, the method is applied to the prescription control of bupivacaine-meloxicam sustained-release solution, which plays a key role.
[0005] The method for reverse analysis of polyorthoester raw materials of the present invention comprises the following steps: firstly, the polyorthoester is degraded, the obtained degradation solution is analyzed by high performance liquid chromatography, and the proportion of monomers in the polyorthoester is calculated according to the analysis result.
[0006] Polyorthoester is a polymer material copolymerized with triethylene glycol, glycolide and 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane as monomers. The theoretical molar ratio of glycolide, ethylene glycol and 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane is (1:4.5:4)-(1:5.5:5), preferably 1:4.5:4, 1:5.5:5.
[0007] The degradation step is to place the polyorthoester in a phosphoric acid aqueous solution with a volume ratio of 1% to 10%, wherein the ratio of the polyorthoester to the phosphoric acid aqueous solution is (1-30) mg:1 mL for preparation, and then destroy it at a high temperature of 37°C to 90°C for 6h to 72h to obtain a degradation solution (the higher the acid concentration and temperature, the faster the degradation rate).
[0008] The chromatographic conditions of the high performance liquid chromatography include: the chromatographic column is filled with octadecylsilane bonded silica gel, the detection wavelength is 190-205nm, the column temperature is 27-35°C, the phosphate buffer solution is used as the mobile phase A, the acetonitrile system is used as the mobile phase B, and the gradient elution is performed, and the gradient elution is:
[0009] The first gradient elution time was 0 min, mobile phase A accounted for 95±1%, and mobile phase B accounted for 5±1%;
[0010] The second gradient elution time was 5±2 min, with mobile phase A accounting for 95±1% and mobile phase B accounting for 5±1%;
[0011] The third gradient elution time was 13±2 min, with mobile phase A accounting for 50±5% and mobile phase B accounting for 50±5%;
[0012] The fourth gradient elution time was 25±2 min, with mobile phase A accounting for 50±5% and mobile phase B accounting for 50±5%;
[0013] The fifth gradient elution time was 25.1±2min, with mobile phase A accounting for 95±1% and mobile phase B accounting for 5±1%;
[0014] The sixth gradient elution time was 45±2 min, with mobile phase A accounting for 95±1% and mobile phase B accounting for 5±1%.
[0015] The phosphate buffer solution is a phosphoric acid aqueous solution with a volume ratio of 0.10%-0.18%.
[0016] The chromatographic conditions of the high performance liquid chromatography also include: using a PDA or UV detector; the mobile phase flow rate is 0.4-0.7 mL / min; the injection volume is 5-30 µL. The preferred chromatographic conditions are: preferred chromatographic column: WePureMicroPμLiteXP T3, specification 4.6 mm×250 mm×5 µm, filler octadecylsilane bonded silica gel;
[0017] Column temperature: 30°C;
[0018] Detection wavelength: 195nm;
[0019] Flow rate: 0.5 mL / min;
[0020] Injection volume: 10 μL;
[0021] Mobile phase: Mobile phase B is acetonitrile system, mobile phase A is 0.10%~0.18% (V / V) phosphoric acid aqueous solution system, gradient elution;
[0022] Gradient elution conditions:
[0023] The first gradient elution time was 0 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%;
[0024] The second gradient elution lasted 5 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%;
[0025] The third gradient elution time was 13 min, with mobile phase A accounting for 50% and mobile phase B accounting for 50%;
[0026] The fourth gradient elution time was 25 min, with mobile phase A accounting for 50% and mobile phase B accounting for 50%;
[0027] The fifth gradient elution time was 25.1 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%;
[0028] The sixth gradient elution time was 45 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%.
[0029] The steps of the described high performance liquid chromatography analysis method are:
[0030] (1) Preparation of reference solution: Take glycolic acid, triethylene glycol and propionic acid reference substances, dissolve them in solvent and quantitatively dilute them to prepare reference solution;
[0031] (2) Preparation of polyorthoester test solution: taking a degradation solution of polyorthoester as the polyorthoester test solution;
[0032] (3) Detection: Take a quantity of solvent, reference solution and poly(orthoester) test solution respectively, and inject them into a liquid chromatograph according to the chromatographic conditions. Record the chromatogram. In the chromatogram of the poly(orthoester) test solution, determine whether there is a chromatographic peak that is consistent with that in the reference solution. Calculate the degradation impurity content by the peak area using the external standard method.
[0033] The solvent is a 1-10% (V:V) phosphoric acid aqueous solution.
[0034] Application of the method for reverse analysis of polyorthoester raw materials: according to the method for reverse analysis of polyorthoester raw materials, the polyorthoester in the method is replaced with bupivacaine-meloxicam sustained-release solution, and the monomer ratio of the polyorthoester in the bupivacaine-meloxicam sustained-release solution is calculated.
[0035] The mass proportion of the auxiliary material polyorthoester in the commercially available bupivacaine-meloxicam sustained-release solution is 624 mg / g.
[0036] The polyorthoester described in the present invention is a polymer material copolymerized with triethylene glycol, glycolide and 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane as monomers. Its degradation process is step-by-step hydrolysis under the erosion of water and acid. The intermediate degradation process is complicated. Figure 1 As shown, it is finally hydrolyzed into small molecular fragments of pentaerythritol, glycolic acid, triethylene glycol and propionic acid. The pentaerythritol and propionic acid fragments are derived from 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane. After degradation of this monomer, one molecule of propionic acid and two molecules of pentaerythritol can be obtained; glycolic acid is derived from glycolide, and triethylene glycol is derived from the monomer itself. The final degradation impurities of POE in vitro are pentaerythritol, glycolic acid, triethylene glycol and propionic acid. The molar percentages of the three monomers can be calculated by detecting the contents of glycolic acid, triethylene glycol and propionic acid.
[0037] The method for reverse analysis of polyorthoester raw materials of the present invention is used to formulate bupivacaine-meloxicam sustained-release solution. Due to the interference of blank solvent and other components in the preparation, the separation degree of pentaerythritol from other impurities does not meet the requirements, and the content of this impurity is not calculated. The purpose is achieved by detecting glycolic acid, triethylene glycol and propionic acid.
[0038] This method can be used to control POE materials and analyze the sustained-release excipient POE in the prescription bupivacaine-meloxicam sustained-release solution, which plays an extremely important role in the development of the sustained-release excipient.
[0039] Compared with the prior art, the present invention has the following beneficial effects:
[0040] (1) The method for reverse analysis of polyorthoester raw materials of the present invention does not rely on nuclear magnetic resonance means. The molar percentage of each monomer is calculated by HPLC content detection method of glycolic acid, triethylene glycol and propionic acid which are finally degraded in vitro from POE, the main sustained-release excipient in bupivacaine-meloxicam sustained-release solution, which plays a key role in POE quality control, process development and prescription analysis.
[0041] (2) The method for reverse analysis of polyorthoester raw materials of the present invention is simple, rapid, highly specific, and highly accurate. It can qualitatively and quantitatively detect a variety of degradation impurities in polyorthoesters. It has important practical significance for the quality control of POE and the reverse analysis of bupivacaine-meloxicam sustained-release solution prescription analysis, and plays an extremely important role in the development of the sustained-release excipient. BRIEF DESCRIPTION OF THE DRAWINGS
[0042] Figure 1 It is a schematic diagram of the degradation process of the polyorthoester of the present invention.
[0043] Figure 2 It is the HPLC chromatogram of the blank solvent of Example 1 and Example 2.
[0044] Figure 3 It is the HPLC chromatogram of the reference substance solution of Example 1 and Example 2.
[0045] Figure 4 The high performance liquid chromatogram of the polyorthoester degradation test solution of Example 1.
[0046] Figure 5 This is a chromatogram of the test solution of the bupivacaine-meloxicam sustained-release solution of Example 2.
[0047] Figure 6 It is the HPLC chromatogram of the blank solvent in the specificity verification of the present invention.
[0048] Figure 7 It is the HPLC chromatogram of the reference solution in the specificity verification of the present invention.
[0049] Figure 8 The figure is a high performance liquid chromatogram of the polyorthoester degradation test solution in the specificity verification of the present invention.
[0050] Fig. 9 The figure is a high performance liquid chromatogram of the degradation solution of the bupivacaine-meloxicam sustained-release solution in the specificity verification of the present invention.
[0051] Fig.10 HPLC chromatograms at different flow rates in the durability verification of the chromatographic conditions of the present invention.
[0052] Fig.11It is the high performance liquid chromatogram of different column temperatures in the durability verification of the chromatographic conditions of the present invention.
[0053] Fig.12 It is a high performance liquid chromatogram of different injection amounts in the durability verification of the chromatographic conditions of the present invention.
[0054] Fig.13 The HPLC chromatograms of different phosphoric acid concentrations of mobile phase A in the durability verification of the chromatographic conditions of the present invention are shown.
[0055] Fig.14 HPLC chromatograms of different elution gradients in the durability verification of the chromatographic conditions of the present invention.
[0056] Fig.15 It is the ultraviolet scanning spectrum of the reference solution triethylene glycol and propionic acid in the method verification of the present invention.
[0057] Fig.16 It is the ultraviolet scanning spectrum of the reference solution triethylene glycol and glycolic acid in the method verification of the present invention. DETAILED DESCRIPTION
[0058] The present invention will be further described below in conjunction with specific embodiments.
[0059] Specifically, the method for reverse analysis of polyorthoester auxiliary materials of the present invention comprises the following steps:
[0060] (1) Dissolve the polyorthoester in a solvent, prepare the solution according to the ratio of the polyorthoester to a 1-10% (V:V) phosphoric acid aqueous solution of (1-30) mg:1 mL, and then dissolve it at 37°C-90°C for 6h-72h to obtain a degradation solution.
[0061] (2) Preparation of reference solution: accurately weigh glycolic acid, triethylene glycol, and propionic acid reference substances, dissolve them in 1-10% (V:V) phosphoric acid aqueous solution, and quantitatively dilute them to make a solution containing 2 mg glycolic acid, 2 mg triethylene glycol, and 2 mg propionic acid per 1 mL as the reference solution;
[0062] The degradation solution of step (1) is used as the poly(orthoester) test solution.
[0063] (3) Detection: Accurately measure the solvent, reference solution and test solution respectively, inject them into liquid chromatograph respectively, record the chromatogram, determine the chromatographic peak consistent with that in the reference solution in the chromatogram of the test solution, calculate the content of each degradation impurity by peak area according to the external standard method, calculate the molar number of the monomer by the content, and thus calculate the ratio of the raw material monomer in the polyorthoester.
[0064] The chromatographic conditions of the high performance liquid chromatography are:
[0065] Chromatographic column: WePureMicroPμLite XP T3, specification 4.6mm×250mm×5µm, filled with octadecylsilane bonded silica gel;
[0066] Detection wavelength: 190-205nm;
[0067] Column temperature: 27-35°C;
[0068] Detector: PDA or UV detector;
[0069] Mobile phase flow rate: 0.4~0.7mL / min;
[0070] Injection volume: 5~30µL;
[0071] Mobile phase: 0.10~0.18% phosphoric acid aqueous solution was used as mobile phase A, and acetonitrile system was used as mobile phase B, and gradient elution was performed. The gradient elution was as follows: the first gradient elution time was 0 min, the mobile phase A accounted for 95±1%, and the mobile phase B accounted for 5±1%; the second gradient elution time was 5±2 min, the mobile phase A accounted for 95±1%, and the mobile phase B accounted for 5±1%; the third gradient elution time was 13±2 min, the mobile phase A accounted for 50±5%, and the mobile phase B accounted for 50±5%; the fourth gradient elution time was 25±2 min, the mobile phase A accounted for 50±5%, and the mobile phase B accounted for 50±5%; the fifth gradient elution time was 25.1±2 min, the mobile phase A accounted for 95±1%, and the mobile phase B accounted for 5±1%; the sixth gradient elution time was 45±2 min, the mobile phase A accounted for 95±1%, and the mobile phase B accounted for 5±1%.
[0072] Specifically, the method for reverse analysis of bupivacaine-meloxicam sustained-release solution of the present invention comprises the following steps:
[0073] (1) The bupivacaine-meloxicam sustained-release solution is dissolved in a solvent at a ratio of (1-30) mg:1 mL of the bupivacaine-meloxicam sustained-release solution and 1-10% (V:V) aqueous phosphoric acid solution, and then dissolved at 37°C-90°C for 6h-72h to obtain a degradation solution.
[0074] (2) Preparation of reference solution: accurately weigh glycolic acid, triethylene glycol, and propionic acid reference substances, dissolve them in 1-10% (V:V) phosphoric acid aqueous solution, and quantitatively dilute them to make a solution containing 1 mg glycolic acid, 2 mg triethylene glycol, and 2 mg propionic acid per 1 mL as the reference solution;
[0075] The degradation solution of step (1) is used as the test solution of bupivacaine-meloxicam sustained-release solution.
[0076] (3) Detection: Accurately measure the solvent, reference solution and test solution respectively, inject them into liquid chromatograph respectively, record the chromatogram, determine the chromatographic peak consistent with that in the reference solution in the chromatogram of the test solution, calculate the content of each degradation impurity by peak area according to the external standard method, calculate the molar number of the monomer by the content, and thus calculate the ratio of each monomer of POE in the bupivacaine-meloxicam sustained-release solution.
[0077] The self-developed auxiliary material POE used in the following examples is a biodegradable material prepared by two-step reactions of ring-opening polymerization and step-by-step polymerization using glycolide, triethylene glycol, and 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane as starting materials. The preparation process is briefly described as follows: glycolide and triethylene glycol are used as starting materials to prepare an intermediate by ring-opening polymerization, and then the intermediate, triethylene glycol and 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane are subjected to step-by-step addition polymerization to obtain a crude POE product, and finally the final product is obtained by purification and solvent removal. Two batches of polyorthoesters were prepared according to the theoretical molar ratios of glycolide, triethylene glycol and 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane of 1:5.5:5 and 1:4.5:4, and were labeled as 24070801 and 24070802, respectively.
[0078] The preparation used is bupivacaine-meloxicam sustained-release solution, which is a commercially available preparation with batch numbers 82525 and 82526, respectively. The mass proportion of the auxiliary material polyorthoester in the commercially available bupivacaine-meloxicam sustained-release solution is 624 mg / g; bupivacaine 29.25 mg / mL, meloxicam 0.88 mg / mL, polyorthoester 730 mg / mL, triacetin 293 mg / mL, dimethyl sulfoxide 117 mg / mL, and maleic acid 0.59 mg / mL.
[0079] Example 1
[0080] The method for reverse analysis of polyorthoester raw materials comprises the following steps:
[0081] (1) Polyorthoester and 5% phosphoric acid aqueous solution (V:V) were prepared in a ratio of 13 mg:1 mL, and then placed at 60°C for 24 hours to obtain a degradation solution.
[0082] (2) Preparation of reference solution: accurately weigh glycolic acid, triethylene glycol, and propionic acid reference substances, dissolve them in 5% (v:v) aqueous phosphoric acid solution, and quantitatively dilute them to make a solution containing 1 mg glycolic acid, 2 mg triethylene glycol, and 2 mg propionic acid per 1 mL. This is used as the reference solution.
[0083] The degradation solution of step (1) is used as the poly(orthoester) test solution.
[0084] A 5% (V:V) phosphoric acid aqueous solution was used as the blank solvent.
[0085] (3) Detection: Accurately measure the solvent, reference solution and test solution respectively, inject them into the liquid chromatograph respectively, record the chromatogram, determine the chromatographic peak consistent with that in the reference solution in the chromatogram of the test solution, and calculate the content of each degradation impurity by peak area according to the external standard method. The reference solution was injected 6 times in parallel, and the test results are shown in Table 1. The calculation results of the glycolic acid content in the test solution are shown in Table 2, the calculation results of the triethylene glycol content are shown in Table 3, and the calculation results of the propionic acid content are shown in Table 4. The HPLC chromatogram of the blank solvent is shown in Figure 2 As shown, the HPLC chromatogram of the reference solution is as shown Figure 3 As shown, the high performance liquid chromatogram of the polyorthoester test solution is as shown Figure 4 shown.
[0086] The chromatographic conditions of the high performance liquid chromatography are:
[0087] Chromatographic column: WePureMicroPμLite XP T3, specification 4.6mm×250mm×5µm, filled with octadecylsilane bonded silica gel;
[0088] Detection wavelength: 195nm;
[0089] Column temperature: 30°C;
[0090] Detector: UV detector;
[0091] Mobile phase flow rate: 0.5 mL / min;
[0092] Injection volume: 10 µL;
[0093] Mobile phase: 0.15% phosphoric acid aqueous solution was used as mobile phase A, and acetonitrile system was used as mobile phase B, and gradient elution was performed. The gradient elution was as follows: the first gradient elution time was 0 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%; the second gradient elution time was 5 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%; the third gradient elution time was 13 min, with mobile phase A accounting for 50% and mobile phase B accounting for 50%; the fourth gradient elution time was 25 min, with mobile phase A accounting for 50% and mobile phase B accounting for 50%; the fifth gradient elution time was 25.1 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%; the sixth gradient elution time was 45 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%.
[0094] Example 2
[0095] Bupivacaine-meloxicam sustained-release solution (containing excipient polyorthoester).
[0096] The method for reverse analysis of polyorthoester raw materials comprises the following steps:
[0097] (1) The bupivacaine-meloxicam sustained-release solution and 5% phosphoric acid aqueous solution (V:V) were prepared in a ratio of 13 mg:1 mL, and then placed at 60°C for 24 h to obtain a degradation solution.
[0098] The degradation solution of step (1) is used as the test solution of bupivacaine-meloxicam sustained-release solution.
[0099] (2) Detection: Accurately measure the test solution, inject it into the liquid chromatograph respectively, and record the chromatogram. The chromatograms of the blank solvent and the reference solution are the chromatograms of Example 1. In the chromatogram of the test solution of bupivacaine-meloxicam sustained-release solution, determine the chromatographic peaks that are consistent with those in the reference solution, and calculate the content of each degradation impurity by peak area according to the external standard method. The chromatogram of the test solution of bupivacaine-meloxicam sustained-release solution is as follows: Figure 5 The calculation results of the glycolic acid content in the test solution are shown in Table 2, the calculation results of the triethylene glycol content are shown in Table 3, and the calculation results of the propionic acid content are shown in Table 4.
[0100] The chromatographic conditions of the HPLC are the same as those in Example 1.
[0101] Table 1 Test results of reference solution
[0102]
[0103] Table 2 Calculation results of glycolic acid content
[0104]
[0105] Table 3 Calculation results of triethylene glycol content
[0106]
[0107] Table 4 Calculation results of propionic acid content
[0108]
[0109] Through Examples 1-2, the content of each degradation impurity in the test polyorthoester and the bupivacaine-meloxicam sustained-release solution test solution can be calculated, and the molar amount of a certain mass of the test substance monomer can be calculated through the content. Through the molar amount, the molar ratio of each monomer in the polyorthoester can be calculated. Among them, Tables 5-7 uniformly calculate the molar amount of degradation impurities based on 100 mg of polyorthoester, and the molar amount calculation results of glycolic acid, triethylene glycol, and propionic acid are shown in Tables 5, 6, and 7, respectively. 1 molecule of POE constituting monomer glycolide can be degraded to generate 2 molecules of glycolic acid, and 1 molecule of POE constituting monomer 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane can be degraded to generate 2 molecules of propionic acid. Attention should be paid when calculating. The calculation results of the molar amount in the monomer are shown in Table 7, wherein 1 molecule of glycolide can produce 2 molecules of glycolic acid. One molecule of 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane can produce two molecules of propionic acid. When calculating, it should be noted that the calculation results of the monomer molar amount are shown in Table 8, and the calculation results of the monomer molar ratio are shown in Table 9.
[0110] Table 5 Calculation results of glycolic acid molar amount
[0111]
[0112] Table 6 Calculation results of triethylene glycol molar amount
[0113]
[0114] Table 7 Propionic acid molar amount calculation results
[0115]
[0116] Table 8 Calculation results of monomer molar amount
[0117]
[0118] Table 9 Calculation results of monomer molar ratio
[0119]
[0120] Conclusion: The molar ratios of the monomers of the excipient polyorthoester (POE) in two batches of commercially available bupivacaine-meloxicam sustained-release solution were basically the same. This method not only analyzed the monomer molar ratio of the excipient polyorthoester used in the commercial product, but also evaluated the difference between the POE produced by itself and the excipient POE used in the commercial bupivacaine-meloxicam sustained-release solution, which can further clarify the quality improvement direction of POE, and is of great significance to the production and control of this excipient.
[0121] Methodological verification of the present invention:
[0122] Standard chromatographic conditions
[0123] Detector: UV detector;
[0124] Chromatographic column: WePureMicroPμLite XP T3, specification 4.6mm×250mm×5µm, filled with octadecylsilane bonded silica gel;
[0125] Column temperature: 30°C;
[0126] Detection wavelength: 195nm;
[0127] Flow rate: 0.5 mL / min;
[0128] Injection volume: 10 μL;
[0129] Mobile phase: Mobile phase B is acetonitrile system, mobile phase A is 0.15% phosphoric acid aqueous solution system, gradient elution;
[0130] Gradient elution conditions:
[0131] The first gradient elution time was 0 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%;
[0132] The second gradient elution lasted 5 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%;
[0133] The third gradient elution time was 13 min, with mobile phase A accounting for 50% and mobile phase B accounting for 50%;
[0134] The fourth gradient elution time was 25 min, with mobile phase A accounting for 50% and mobile phase B accounting for 50%;
[0135] The fifth gradient elution time was 25.1 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%;
[0136] The sixth gradient elution time was 45 min, with mobile phase A accounting for 95% and mobile phase B accounting for 5%.
[0137] Blank solvent: 5% phosphoric acid aqueous solution (take 5 mL of phosphoric acid and place it in a 100 mL volumetric flask, dilute to the scale with water, and shake well).
[0138] 1. Specificity verification
[0139] Mixed solution: Take pentaerythritol, glycolic acid, triethylene glycol and propionic acid reference substances, accurately weigh them, dissolve them in solvent and quantitatively dilute them to make a solution containing 1 mg of glycolic acid, 2 mg of pentaerythritol, triethylene glycol and propionic acid per 1 mL.
[0140] POE degradation solution: Take the test sample, weigh it accurately, put it in an ampoule, add the solvent quantitatively to make a solution containing 8 mg per 1 mL, seal it, place it in a 60℃ oven for 24 hours, and shake it well.
[0141] Application preparation prescription (bupivacaine-meloxicam sustained-release solution) Degradation solution: Take the bupivacaine-meloxicam sustained-release solution test sample, accurately weigh it, put it in an ampoule, add the solvent quantitatively to make a solution containing 13 mg per 1 mL, seal it, place it in a 60°C oven for 24 hours, and shake it well.
[0142] Precisely measure the blank solvent, the mixed solution and the two degradation solutions, inject them according to the above chromatographic conditions, and record the chromatogram. The results are shown in Table 10. The HPLC chromatogram of the specific blank solvent is shown in Table 10. Figure 6 The HPLC chromatogram of the specific reference solution is shown in Figure 7 As shown, the HPLC chromatogram of the specific poly(orthoester) degradation test solution is as follows Figure 8 As shown, the HPLC chromatogram of the degradation solution of the specific bupivacaine-meloxicam sustained-release solution is as follows Fig. 9 shown.
[0143] Table 10 Specificity test results
[0144]
[0145] Conclusion: The above data show that the separation degree of all impurities except pentaerythritol in each solution is greater than 1.0, which meets the requirements for detecting impurity content and has good method specificity. Due to interference from other impurities in the prescription, the separation degree of pentaerythritol and adjacent impurities is small, which will affect the content detection, so the impurity is not detected. The impurity has a 1:2 relationship with propionic acid, and the purpose can be achieved by detecting propionic acid alone. This shows that this method can simultaneously detect the content of POE and the three degradation impurities of POE in the prescription, and has good specificity.
[0146] 2. System Precision Verification
[0147] Reference solution: Take pentaerythritol, glycolic acid, triethylene glycol and propionic acid reference substances, accurately weigh them, dissolve them in solvent and quantitatively dilute them to make a solution containing 1 mg of glycolic acid, 2 mg of pentaerythritol, triethylene glycol and propionic acid per 1 mL.
[0148] Accurately measure the reference solution and inject it according to the above chromatographic conditions, record the chromatogram, and calculate the relative standard deviation (RSD) of the peak area of each peak after 6 consecutive injections of the reference solution. The results are shown in Table 11. Figure 3 .
[0149] Table 11 System precision test results
[0150]
[0151] Conclusion: The reference solution was injected 6 times continuously, and the maximum RSD of the reference peak area was 0.4%, indicating that the system precision was good.
[0152] 3. Verification of Quantitation Limit
[0153] Using the solvent as blank, adjust the instrument sensitivity, record the instrument noise level within the peak time range of the analyte, and calculate the average noise.
[0154] Limit of quantitation: Accurately prepare the reference solution of the substance to be measured, gradually dilute it to a certain concentration and inject it, and measure it three times in a row. Calculate the ratio of its peak height to noise (signal-to-noise ratio). The sample concentration with a signal-to-noise ratio (S / N) above 10 is the limit of quantitation concentration, and its ratio to the theoretical sample concentration is the limit of quantitation.
[0155] Stock solution of pentaerythritol reference substance: take 100 mg of pentaerythritol reference substance, place it in a 10 mL volumetric flask, dissolve it with solvent and dilute it to the scale, shake well; accurately measure 0.4 mL, place it in a 10 mL volumetric flask, add solvent to dilute it to the scale, shake well.
[0156] Stock solution of glycolic acid reference substance: take 100 mg of glycolic acid reference substance, place it in a 10 mL volumetric flask, dissolve it with solvent and dilute it to the scale, shake well (concentrated stock solution); accurately measure 0.2 mL, place it in a 10 mL volumetric flask, add solvent to dilute it to the scale, and shake well.
[0157] Stock solution of triethylene glycol reference substance: Take 100 mg of triethylene glycol reference substance, place it in a 10 mL volumetric flask, dissolve it with solvent and dilute it to the scale, shake well; accurately measure 0.2 mL, place it in a 10 mL volumetric flask, add solvent to dilute it to the scale, and shake well.
[0158] Propionic acid reference substance stock solution: Take 100 mg of propionic acid reference substance, place it in a 10 mL volumetric flask, dissolve it with solvent and dilute it to the scale, shake well; accurately measure 0.4 mL, place it in a 10 mL volumetric flask, add solvent to dilute it to the scale, and shake well.
[0159] Quantitation limit solution: Accurately measure 1.0 mL of pentaerythritol reference stock solution, 0.3 mL of glycolic acid reference stock solution, 1.0 mL of triethylene glycol reference stock solution, and 0.3 mL of propionic acid reference stock solution, place in a 10 mL volumetric flask, add solvent to dilute to the scale, and shake well.
[0160] The solvent and the quantitative limit solution were accurately measured and injected into the liquid chromatograph respectively. The quantitative limit solution was injected three times continuously. The chromatogram was recorded and the signal-to-noise ratio was calculated. The results are shown in Table 12.
[0161] Table 12 Quantitation limit determination results
[0162]
[0163] Conclusion: Under this method, the sensitivity of each degradation impurity of POE meets the requirements.
[0164] 4. Linear verification
[0165] Linear stock solution: Take 160 mg each of pentaerythritol, triethylene glycol, propionic acid and 80 mg of glycolic acid, accurately weigh, place in a 40 mL volumetric flask, dissolve and dilute to the scale with solvent, and shake well.
[0166] Limit of Quantitation: Use the limit of quantitation result under "Limit of Quantitation"
[0167] Linear solution 1: Accurately measure 1.0 mL of the linear solution stock solution, place it in a 10 mL volumetric flask, dilute to the scale with solvent, and shake well.
[0168] Linear solution 2: Accurately measure 2.0 mL of the linear solution stock solution, place it in a 10 mL volumetric flask, dilute to the scale with solvent, and shake well.
[0169] Linear solution 3: Accurately measure 2.5 mL of the linear solution stock solution, place it in a 10 mL volumetric flask, dilute to the scale with solvent, and shake well.
[0170] Linear solution 4: Accurately measure 4.0 mL of the linear solution stock solution, place it in a 10 mL volumetric flask, dilute to the scale with solvent, and shake well.
[0171] Linear solution 5: Accurately measure 5.0 mL of the linear solution stock solution, place it in a 10 mL volumetric flask, dilute to the scale with solvent, and shake well.
[0172] Linear solution 6: Accurately measure 6.0 mL of the linear solution stock solution, place it in a 10 mL volumetric flask, dilute to the scale with solvent, and shake well.
[0173] Linear solution 7: Accurately measure 7.5 mL of the linear solution stock solution, place it in a 10 mL volumetric flask, dilute to the scale with solvent, and shake well.
[0174] Accurately measure the above-mentioned linear solutions of different concentrations, inject them into the liquid chromatograph respectively, record the chromatogram, draw a regression curve with concentration versus corresponding peak area, calculate the regression equation and the corresponding linear correlation coefficient. The results are shown in Tables 13-16.
[0175] Table 13 Pentaerythritol linear test results
[0176]
[0177] Table 14 Glycolic acid linearity test results
[0178]
[0179] Table 15 Triethylene glycol linear test results
[0180]
[0181] Table 16 Propionic acid linear test results
[0182]
[0183] Conclusion: Within their respective concentration ranges, the linear correlation coefficients of the four impurities are all greater than 0.990, indicating a good linear relationship.
[0184] (V) Stability verification
[0185] POE degradation solution: Take the test sample, weigh it accurately, put it in an ampoule, add the solvent quantitatively to make a solution containing 8 mg per 1 mL, seal it, place it in a 60℃ oven for 24 hours, and shake it well.
[0186] Application preparation prescription (bupivacaine-meloxicam sustained-release solution) Degradation solution: Take the bupivacaine-meloxicam sustained-release solution test sample, accurately weigh it, put it in an ampoule, add the solvent quantitatively to make a solution containing 8 mg per 1 mL, seal it, place it in a 60°C oven for 24 hours, and shake it well.
[0187] Take the above solution, degrade it at high temperature (60℃) for 24h, and then inject it into the liquid chromatograph at different time periods to record the chromatogram. Investigate the stability of the degraded solution. If the stability is good and there is no obvious growth trend of each impurity, it means that the destruction is complete. The results are shown in Tables 17~18.
[0188] Table 17 POE degradation solution stability test results
[0189]
[0190] Table 18 Bupivacaine-meloxicam sustained release solution degradation solution stability test results
[0191]
[0192] Conclusion: There is no obvious change in the peak area of the above impurities at different times, indicating that the stability is good during the storage time and the in vitro degradation has been completed. The 24h destruction time fully meets the requirements. At this time, the solution can be tested for the content of degraded impurities.
[0193] (VI) Durability Verification
[0194] 1. Investigation of degradation conditions
[0195] Take equal amounts of POE and bupivacaine-meloxicam sustained-release solution from the same batch and prepare degradation solutions according to the maximum concentration in the presence of different concentrations of phosphoric acid solvents. Destruction of the test samples was carried out under the upper limit (90℃ / 6h), upper limit (37℃ / 72h) and standard conditions. If the degradation impurity peaks obtained are consistent with those under standard conditions, it means that the degradation conditions are applicable.
[0196] Degradation conditions of the test sample: Take an appropriate amount of the test sample, weigh it accurately, put it in an ampoule, add 10mL of solvent quantitatively, seal it, destroy it under high temperature conditions, and shake it well. Prepare the solution according to Table 19. Take 60℃ / 24h as the standard condition.
[0197] Take each solution, inject it into the liquid chromatograph respectively, record the chromatogram, and compare the parallelism of the detection area of degradation impurities.
[0198] Table 19 Results of investigation on degradation conditions
[0199]
[0200] Conclusion: Under the maximum concentration of the test sample, the degradation temperature, degradation time and degradation solvent phosphoric acid concentration were investigated. Under the condition of equal amount of test sample (30 mg / mL), the peak areas of the three impurities obtained after degradation were basically consistent with those under standard conditions. Therefore, it is shown that the test sample concentration (1-30) mg:1mL set by the present invention, the destruction condition of high temperature destruction at 37℃-90℃ for 6h-72h, and the degradation solvent phosphoric acid concentration (1%~10%) are applicable.
[0201] 2. Chromatographic conditions durability
[0202] The chromatographic conditions used in the method validation were used as standard conditions, and the test solution in Example 1 was used as the system suitability solution to investigate the durability of the chromatographic conditions. In the durability experiment, when the other chromatographic conditions were the same as those in the method validation, the principle of a single variable was adopted, and only one of the conditions was changed for investigation.
[0203] Study condition 1: column flow rate lower limit 0.4mL / min, column flow rate upper limit 0.7mL / min. Study the durability of different flow rates, the HPLC chromatogram is as follows Fig.10 As shown, 10-1 is a high performance liquid chromatogram with a flow rate of 0.4 mL / min, 10-2 is a high performance liquid chromatogram with a flow rate of 0.5 mL / min, and 10-3 is a high performance liquid chromatogram with a flow rate of 0.7 mL / min.
[0204] Study condition 2: column temperature lower limit 27℃, column temperature upper limit 35℃. Study the durability of different column temperatures. The HPLC chromatogram is as follows: Fig.11 As shown, 11-1 is a high performance liquid chromatogram at a column temperature of 35°C, 11-2 is a high performance liquid chromatogram at a column temperature of 30°C, and 11-3 is a high performance liquid chromatogram at a column temperature of 27°C.
[0205] Study condition 3: The lower limit of injection volume is 5μL, and the upper limit of injection volume is 30μL. The durability of different injection volumes is studied. The HPLC chromatogram is as follows: Fig.12As shown, 12-1 is the HPLC chromatogram with an injection volume of 30 μL, 12-2 is the HPLC chromatogram with an injection volume of 10 μL, and 12-3 is the HPLC chromatogram with an injection volume of 5 μL.
[0206] Study condition 4: The lower limit of phosphoric acid concentration in mobile phase A is 0.10% phosphoric acid, and the upper limit is 0.18% phosphoric acid. The durability of different phosphoric acid concentrations in mobile phase A was investigated. The HPLC chromatogram is shown in Figure 4. Fig.13 As shown, 13-1 is the HPLC chromatogram of 0.10% phosphoric acid, 13-2 is the HPLC chromatogram of 0.15% phosphoric acid, and 13-3 is the HPLC chromatogram of 0.18% phosphoric acid.
[0207] Study condition 5: Gradient upper limit, gradient lower limit. Study the durability of different elution gradients. The HPLC chromatogram is as follows: Fig.14 As shown, 14-1 is the HPLC chromatogram of the upper limit of the gradient, 14-2 is the HPLC chromatogram of the standard elution gradient (using the elution gradient in the method validation), and 14-3 is the HPLC chromatogram of the lower limit of the gradient.
[0208] The upper limit of the gradient is:
[0209] The first gradient elution time was 0 min, mobile phase A accounted for 94%, and mobile phase B accounted for 6%;
[0210] The second gradient elution time was 3 min, with mobile phase A accounting for 94% and mobile phase B accounting for 6%;
[0211] The third gradient elution time was 11 min, with mobile phase A accounting for 45% and mobile phase B accounting for 55%;
[0212] The fourth gradient elution time was 23 min, with mobile phase A accounting for 45% and mobile phase B accounting for 55%;
[0213] The fifth gradient elution time was 23.1 min, with mobile phase A accounting for 94% and mobile phase B accounting for 6%;
[0214] The sixth gradient elution time was 43 min, with mobile phase A accounting for 94% and mobile phase B accounting for 6%.
[0215] The gradient lower limit is:
[0216] The first gradient elution time was 0 min, mobile phase A accounted for 96%, and mobile phase B accounted for 4%;
[0217] The second gradient elution time was 7 min, with mobile phase A accounting for 96% and mobile phase B accounting for 4%;
[0218] The third gradient elution time was 15 min, with mobile phase A accounting for 55% and mobile phase B accounting for 45%;
[0219] The fourth gradient elution time was 27 min, with mobile phase A accounting for 55% and mobile phase B accounting for 45%;
[0220] The fifth gradient elution time was 27.1 min, with mobile phase A accounting for 96% and mobile phase B accounting for 4%;
[0221] The sixth gradient elution time was 47 min, with mobile phase A accounting for 96% and mobile phase B accounting for 4%.
[0222] Take the test sample solution, inject it into the liquid chromatograph under standard conditions and the above conditions respectively, and record the chromatogram.
[0223] Conclusion: The comparison chart shows that the upper and lower limits under each condition can meet the requirements for degradation impurity detection.
[0224] 3. Wavelength selection
[0225] Other standard chromatographic conditions used in method validation were used, with the UV detector replaced by a PDA detector, and wavelength scanning was performed on the three impurities of propionic acid, triethylene glycol, and glycolic acid in the reference solution in Example 1. Other chromatographic conditions were the same as those used in method validation. The test results were as follows: Fig.15 and Fig.16 As shown. Fig.15 a is the UV scanning spectrum of triethylene glycol, b is the UV scanning spectrum of propionic acid, Fig.16 Figure c is the UV scanning spectrum of glycolic acid.
[0226] Depend on Fig.15 and Fig.16 It can be seen that triethylene glycol is the terminal absorption, glycolic acid and propionic acid both have ultraviolet absorption between 190nm and 220nm. In order to detect the three degradation impurities at the same time, the wavelength setting range is between 190nm and 205nm.
Claims
1. A method for reverse analysis of polyorthoester raw materials, characterized in that: The following steps are involved: Degrading the polyorthoester, and analyzing the obtained degradation solution by high performance liquid chromatography, and calculating the ratio of monomers in the polyorthoester according to the analysis result, specifically, calculating the molar percentages of the three monomers by detecting the contents of glycolic acid, triethylene glycol, and propionic acid; Polyorthoester is a polymer material copolymerized with triethylene glycol, glycolide and 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane as monomers. The theoretical molar ratio of triethylene glycolide, ethylene glycol and 3,9-diethylene-2,4,8,10-tetraoxaspiro[5,5]undecane is (1:4.5:4)-(1:5.5:5). The degradation step is to place the polyorthoester in a phosphoric acid aqueous solution with a volume ratio of 1% to 10%, wherein the ratio of the polyorthoester to the phosphoric acid aqueous solution is (1-30) mg:1 mL, and then destroy it at 37°C-90°C for 6h-72h to obtain a degradation solution.
2. The method for reverse analysis of polyorthoester raw materials according to claim 1, characterized in that: The chromatographic conditions of the high performance liquid chromatography include: the chromatographic column is filled with octadecylsilane bonded silica gel, the detection wavelength is 190-205nm, the column temperature is 27-35°C, the phosphate buffer solution is used as the mobile phase A, the acetonitrile system is used as the mobile phase B, and the gradient elution is performed, and the gradient elution is: The first gradient elution time was 0 min, mobile phase A accounted for 95±1%, and mobile phase B accounted for 5±1%; The second gradient elution time was 5±2 min, with mobile phase A accounting for 95±1% and mobile phase B accounting for 5±1%; The third gradient elution time was 13±2 min, with mobile phase A accounting for 50±5% and mobile phase B accounting for 50±5%; The fourth gradient elution time was 25±2 min, with mobile phase A accounting for 50±5% and mobile phase B accounting for 50±5%; The fifth gradient elution time was 25.1±2min, with mobile phase A accounting for 95±1% and mobile phase B accounting for 5±1%; The sixth gradient elution time was 45±2 min, with mobile phase A accounting for 95±1% and mobile phase B accounting for 5±1%.
3. The method for reverse analysis of polyorthoester raw materials according to claim 2, characterized in that: The phosphate buffer solution is a phosphoric acid aqueous solution with a volume ratio of 0.10%-0.18%.
4. The method for reverse analysis of polyorthoester raw materials according to claim 2, characterized in that: The chromatographic conditions of the high performance liquid chromatography also include: using a PDA or ultraviolet detector; the mobile phase flow rate is 0.4-0.7mL / min; and the injection volume is 5-30μL.
5. The method for reverse analysis of polyorthoester raw materials according to claim 1, characterized in that: The steps of the described high performance liquid chromatography analysis method are: (1) Preparation of reference solution: Take glycolic acid, triethylene glycol and propionic acid reference substances, dissolve them in solvent and quantitatively dilute them to prepare reference solution; (2) Preparation of polyorthoester test solution: taking a degradation solution of polyorthoester as the polyorthoester test solution; (3) Detection: Take a quantity of solvent, reference solution and poly(orthoester) test solution respectively, and inject them into a liquid chromatograph according to the chromatographic conditions. Record the chromatogram. In the chromatogram of the poly(orthoester) test solution, determine whether there is a chromatographic peak that is consistent with that in the reference solution. Calculate the degradation impurity content by the peak area using the external standard method.
6. The method for reverse analysis of polyorthoester raw materials according to claim 5, characterized in that: The solvent is a phosphoric acid aqueous solution with a volume ratio of 1% to 10%.
7. An application of the method for reverse analysis of polyorthoester raw materials according to any one of claims 1 to 6, characterized in that: According to the method of reverse analysis of polyorthoester raw materials, the polyorthoester in the method was replaced by bupivacaine-meloxicam sustained-release solution, and the monomer ratio of the auxiliary material polyorthoester in the bupivacaine-meloxicam sustained-release solution was calculated.
